Genetic-Based Biomarkers and Next-Generation Sequencing: The Future of Personalized Care in Colorectal Cancer

• Fry R , MahmoudN, MaronD, RossH, RombeauJ: Colon and rectum. In: Sabiston Textbook of Surgery (8th Edition). Townsend C, Beauchamp R, Evers B, Mattox K (Eds). Saunders, Elsevier, PA, USA (2008).
   Google Scholar
• Engstrom P , ArnolettiJ, BensonAB 3rd et al.: NCCN guidelines: Colon Cancer. Version 1.2011 (2010).
   Google Scholar
• Vogelstein B , FearonER, HamiltonSR et al.: Genetic alterations during colorectal-tumor development.N. Engl. J. Med.319(9) , 525–532 (1988).
   PubMed Web of Science ®Google Scholar
• Gunderson LL , JessupJM, SargentDJ, GreeneFL, StewartAK: Revised TN categorization for colon cancer based on national survival outcomes data.J. Clin. Oncol.28(2) , 264–271 (2010).
   PubMed Web of Science ®Google Scholar
• Marshall JL : Risk assessment in stage II colorectal cancer.Oncology (Williston Park)24(1 Suppl. 1) , 9–13 (2010).
   PubMed Web of Science ®Google Scholar
• Gray R , BarnwellJ, McConkeyC et al.: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.Lancet370(9604) , 2020–2029 (2007).
   PubMed Web of Science ®Google Scholar
• Becquemont L : Pharmacogenomics of adverse drug reactions: practical applications and perspectives.Pharmacogenomics10(6) , 961–969 (2009).
   PubMed Web of Science ®Google Scholar
• Locker GY , HamiltonS, HarrisJ et al.: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.J. Clin. Oncol.24(33) , 5313–5327 (2006).
   PubMed Web of Science ®Google Scholar
• Peltomaki P : Role of DNA mismatch repair defects in the pathogenesis of human cancer.J. Clin. Oncol.21(6) , 1174–1179 (2003).
   PubMed Web of Science ®Google Scholar
• Boland CR , ThibodeauSN, HamiltonSR et al.: A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.Cancer Res.58(22) , 5248–5257 (1998).
   PubMed Web of Science ®Google Scholar
• Popat S , HubnerR, HoulstonRS: Systematic review of microsatellite instability and colorectal cancer prognosis.J. Clin. Oncol.23(3) , 609–618 (2005).
   PubMed Web of Science ®Google Scholar
• Benatti P , GafaR, BaranaD et al.: Microsatellite instability and colorectal cancer prognosis.Clin. Cancer Res.11(23) , 8332–8340 (2005).
   PubMed Web of Science ®Google Scholar
• Kim GP , ColangeloLH, WieandHS et al.: Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute–National Surgical Adjuvant Breast and Bowel Project Collaborative Study.J. Clin. Oncol.25(7) , 767–772 (2007).
   PubMed Web of Science ®Google Scholar
• Ribic CM , SargentDJ, MooreMJ et al.: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.N. Engl. J. Med.349(3) , 247–257 (2003).
   PubMed Web of Science ®Google Scholar
• Bertagnolli MM , NiedzwieckiD, ComptonCC et al.: Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.J. Clin. Oncol.27(11) , 1814–1821 (2009).
   PubMed Web of Science ®Google Scholar
• Des Guetz G , SchischmanoffO, NicolasP et al.: Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis.Eur. J. Cancer45(10) , 1890–1896 (2009).
   PubMed Web of Science ®Google Scholar
• Sargent DJ , MarsoniS, MongesG et al.: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.J. Clin. Oncol.28(20) , 3219–3226 (2010).
   PubMed Web of Science ®Google Scholar
• Munro AJ , LainS, LaneDP: P53 abnormalities and outcomes in colorectal cancer: a systematic review.Br. J. Cancer92(3) , 434–444 (2005).
   PubMed Web of Science ®Google Scholar
• Font A , AbadA, MonzoM et al.: Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer.Dis. Colon Rectum44(4) , 549–557 (2001).
   PubMed Web of Science ®Google Scholar
• Jernvall P , MakinenMJ, KarttunenTJ, MakelaJ, VihkoP: Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers.Br. J. Cancer79(5–6) , 903–908 (1999).
   PubMed Web of Science ®Google Scholar
• Lanza G , MatteuzziM, GafaR et al.: Chromosome 18q allelic loss and prognosis in stage II and III colon cancer.Int. J. Cancer79(4) , 390–395 (1998).
   PubMed Web of Science ®Google Scholar
• Watanabe T , WuTT, CatalanoPJ et al.: Molecular predictors of survival after adjuvant chemotherapy for colon cancer.N. Engl. J. Med.344(16) , 1196–1206 (2001).
   PubMed Web of Science ®Google Scholar
• Fearon ER : Molecular genetics of colorectal cancer.Ann. NY Acad. Sci.768 , 101–110 (1995).
   PubMed Web of Science ®Google Scholar
• Kirley SD , D‘ApuzzoM, LauwersGY et al.: The cables gene on chromosome 18Q regulates colon cancer progression in vivo.Cancer Biol. Ther.4(8) , 861–863 (2005).
   PubMed Web of Science ®Google Scholar
• Carethers JM , HawnMT, GreensonJK, HitchcockCL, BolandCR: Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer.Gastroenterology114(6) , 1188–1195 (1998).
   PubMed Web of Science ®Google Scholar
• Cohn KH , OrnsteinDL, WangF et al.: The significance of allelic deletions and aneuploidy in colorectal carcinoma. Results of a 5-year follow-up study.Cancer79(2) , 233–244 (1997).
   PubMed Web of Science ®Google Scholar
• Longley DB , HarkinDP, JohnstonPG: 5-fluorouracil: mechanisms of action and clinical strategies.Nat. Rev. Cancer3(5) , 330–338 (2003).
   PubMed Web of Science ®Google Scholar
• Popat S , MatakidouA, HoulstonRS: Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis.J. Clin. Oncol.22(3) , 529–536 (2004).
   PubMed Web of Science ®Google Scholar
• Boige V , MendiboureJ, PignonJP et al.: Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000–2005.J. Clin. Oncol.28(15) , 2556–2564 (2010).
   PubMedGoogle Scholar
• Martinez-Balibrea E , AbadA, Martinez-CardusA et al.: UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.Br. J. Cancer103(4) , 581–589 (2010).
   PubMed Web of Science ®Google Scholar
• Jakobsen A , NielsenJN, GyldenkerneN, LindebergJ: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity.J. Clin. Oncol.23(7) , 1365–1369 (2005).
   PubMed Web of Science ®Google Scholar
• Etienne-Grimaldi MC , MilanoG, Maindrault-GoebelF et al.: Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.Br. J. Clin. Pharmacol.69(1) , 58–66 (2010).
   PubMed Web of Science ®Google Scholar
• Zintzaras E , ZiogasDC, KitsiosGD et al.: MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis.Pharmacogenomics10(8) , 1285–1294 (2009).
   PubMed Web of Science ®Google Scholar
• Lievre A , BlonsH, Laurent-PuigP: Oncogenic mutations as predictive factors in colorectal cancer.Oncogene29(21) , 3033–3043 (2010).
   PubMed Web of Science ®Google Scholar
• Roth AD , TejparS, DelorenziM et al.: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial.J. Clin. Oncol.28(3) , 466–474 (2010).
   PubMed Web of Science ®Google Scholar
• Andreyev HJ , NormanAR, CunninghamD, OatesJR, ClarkePA: Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study.J. Natl Cancer Inst.90(9) , 675–684 (1998).
   PubMed Web of Science ®Google Scholar
• Andreyev HJ , NormanAR, CunninghamD et al.: Kirsten Ras mutations in patients with colorectal cancer: the ‘RASCAL II‘ study.Br. J. Cancer85(5) , 692–696 (2001).
   PubMed Web of Science ®Google Scholar
• Peeters M , PriceTJ, CervantesA et al.: Randomized Phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.J. Clin. Oncol.28(31) , 4706–4713 (2010).
   PubMed Web of Science ®Google Scholar
• De Roock W , ClaesB, BernasconiD et al.: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol.11(8) , 753–762 (2010).
   PubMed Web of Science ®Google Scholar
• Qiu LX , MaoC, ZhangJ et al.: Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies.Eur. J. Cancer46(15) , 2781–2787 (2010).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C , BondarenkoI, MakhsonA et al.: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.J. Clin. Oncol.27(5) , 663–671 (2009).
   PubMed Web of Science ®Google Scholar
• Ocvirk J , BrodowiczT, WrbaF et al.: Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.World J. Gastroenterol.16(25) , 3133–3143 (2010).
   PubMed Web of Science ®Google Scholar
• Tol J , KoopmanM, CatsA et al.: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.N. Engl. J. Med.360(6) , 563–572 (2009).
   PubMed Web of Science ®Google Scholar
• Amado RG , WolfM, PeetersM et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.J. Clin. Oncol.26(10) , 1626–1634 (2008).
   PubMed Web of Science ®Google Scholar
• Lievre A , BachetJB, BoigeV et al.: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.J. Clin. Oncol.26(3) , 374–379 (2008).
   PubMed Web of Science ®Google Scholar
• Karapetis CS , Khambata-FordS, JonkerDJ et al.: K-ras mutations and benefit from cetuximab in advanced colorectal cancer.N. Engl. J. Med.359(17) , 1757–1765 (2008).
   PubMed Web of Science ®Google Scholar
• Benvenuti S , Sartore-BianchiA, Di Nicolantonio F et al.: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res.67(6) , 2643–2648 (2007).
   PubMed Web of Science ®Google Scholar
• Loupakis F , PollinaL, StasiI et al.: PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.J. Clin. Oncol.27(16) , 2622–2629 (2009).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , KohneCH, HitreE et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.N. Engl. J. Med.360(14) , 1408–1417 (2009).
   PubMed Web of Science ®Google Scholar
• Rajagopalan H , BardelliA, LengauerC et al.: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.Nature418(6901) , 934 (2002).
   PubMed Web of Science ®Google Scholar
• Laurent-Puig P , CayreA, ManceauG et al.: Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.J. Clin. Oncol.27(35) , 5924–5930 (2009).
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F , MartiniM, MolinariF et al.: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.J. Clin. Oncol.26(35) , 5705–5712 (2008).
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A , Di Nicolantonio F, Nichelatti M et al.: Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS ONE4(10) , e7287 (2009).
   PubMed Web of Science ®Google Scholar
• Rogers J : The finished genome sequence of Homo sapiens.Cold Spring Harb. Symp. Quant. Biol.68 , 1–11 (2003).
   PubMedGoogle Scholar
• Ansorge WJ : Next-generation DNA sequencing techniques.Nat. Biotechnol.25(4) , 195–203 (2009).
   Google Scholar
• Shendure J , JiH: Next-generation DNA sequencing.Nat. Biotechnol.26(10) , 1135–1145 (2008).
   PubMed Web of Science ®Google Scholar
• Metzker ML : Sequencing technologies – the next generation.Nat. Rev. Genet.11(1) , 31–46 (2010).
   PubMed Web of Science ®Google Scholar
• Medvedev P , StanciuM, BrudnoM: Computational methods for discovering structural variation with next-generation sequencing.Nat. Methods6(Suppl. 11) , S13–S20 (2009).
   PubMed Web of Science ®Google Scholar
• McPherson JD : Next-generation gap.Nat. Methods6(Suppl. 11) , S2–S5 (2009).
   PubMed Web of Science ®Google Scholar
• Meyerson M , GabrielS, GetzG: Advances in understanding cancer genomes through second-generation sequencing.Nat. Rev. Genet.11(10) , 685–696 (2010).
   PubMed Web of Science ®Google Scholar
• Bentley DR , BalasubramanianS, SwerdlowHP et al.: Accurate whole human genome sequencing using reversible terminator chemistry.Nature456(7218) , 53–59 (2008).
   PubMed Web of Science ®Google Scholar
• Ahn SM , KimTH, LeeS et al.: The first Korean genome sequence and analysis: full genome sequencing for a socio-ethnic group.Genome Res.19(9) , 1622–1629 (2009).
   PubMed Web of Science ®Google Scholar
• Wheeler DA , SrinivasanM, EgholmM et al.: The complete genome of an individual by massively parallel DNA sequencing.Nature452(7189) , 872–876 (2008).
   PubMed Web of Science ®Google Scholar
• Harris M , WinshipI, SpriggsM: Controversies and ethical issues in cancer – genetics clinics.Lancet Oncol.6(5) , 301–310 (2005).
   PubMed Web of Science ®Google Scholar
• Stanley AJ , GaffCL, AittomakiAK et al.: Value of predictive genetic testing in management of hereditary non-polyposis colorectal cancer (HNPCC).Med. J. Aust.172(7) , 313–316 (2000).
   PubMed Web of Science ®Google Scholar
• Thomas RK , GreulichH, YuzaY et al.: Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.Cold Spring Harb. Symp. Quant. Biol.70 , 73–81 (2005).
   PubMedGoogle Scholar
• Mardis ER , DingL, DoolingDJ et al.: Recurring mutations found by sequencing an acute myeloid leukemia genome.N. Engl. J. Med.361(11) , 1058–1066 (2009).
   PubMed Web of Science ®Google Scholar
• Ley TJ , MardisER, DingL et al.: DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.Nature456(7218) , 66–72 (2008).
   PubMed Web of Science ®Google Scholar
• Berger MF , LevinJZ, VijayendranK et al.: Integrative analysis of the melanoma transcriptome.Genome Res.20(4) , 413–427 (2010).
   PubMed Web of Science ®Google Scholar
• Bueno R , De Rienzo A, Dong L et al.: Second generation sequencing of the mesothelioma tumor genome. PLoS ONE5(5) , e10612 (2010).
   PubMed Web of Science ®Google Scholar
• Pleasance ED , StephensPJ, O‘MearaS et al.: A small-cell lung cancer genome with complex signatures of tobacco exposure.Nature463(7278) , 184–190 (2010).
   PubMed Web of Science ®Google Scholar
• Yu J , ManiRS, CaoQ et al.: An integrated network of androgen receptor, polycomb, and TMPRSS2–ERG gene fusions in prostate cancer progression.Cancer Cell17(5) , 443–454 (2010).
   PubMed Web of Science ®Google Scholar
• Wood LD , ParsonsDW, JonesS et al.: The genomic landscapes of human breast and colorectal cancers.Science318(5853) , 1108–1113 (2007).
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J. Clin. Oncol.21(12) , 2397–2406 (2003).
   PubMed Web of Science ®Google Scholar
• Health law – genetics – Congress restricts use of genetic information by insurers and employers. Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110–233, 122 Stat. 881 (to be codified in scattered sections of 26, 29, and 42 U.S.C.). Harv. Law Rev.122(3) , 1038–1045 (2009).
   PubMedGoogle Scholar
• Offit K , ThomP: Ethical and legal aspects of cancer genetic testing.Semin. Oncol.34(5) , 435–443 (2007).
   PubMed Web of Science ®Google Scholar
• Stadler ZK , ThomP, RobsonME et al.: Genome-wide association studies of cancer.J. Clin. Oncol.28(27) , 4255–4267 (2010).
   PubMed Web of Science ®Google Scholar
• Subramanian J , SimonR: Gene expression-based prognostic signatures in lung cancer: ready for clinical use?J. Natl Cancer Inst.102(7) , 464–474 (2010).
   PubMed Web of Science ®Google Scholar
• Garman KS , AcharyaCR, EdelmanE et al.: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities.Proc. Natl Acad. Sci. USA105(49) , 19432–19437 (2008).
   PubMed Web of Science ®Google Scholar
• Ali MA , SjoblomT: Molecular pathways in tumor progression: from discovery to functional understanding.Mol. Biosyst.5(9) , 902–908 (2009).
   PubMedGoogle Scholar
• Vilar E , GruberSB: Microsatellite instability in colorectal cancer – the stable evidence.Nat. Rev. Clin. Oncol.7(3) , 153–162 (2010).
   PubMed Web of Science ®Google Scholar
• Gstaiger M , AebersoldR: Applying mass spectrometry-based proteomics to genetics, genomics and network biology.Nat. Rev. Genet.10(9) , 617–627 (2009).
   PubMed Web of Science ®Google Scholar
• Kandpal R , SaviolaB, FeltonJ: The era of ‘omics unlimited.Biotechniques46(5) , 351–352, 4–5 (2009).
   PubMed Web of Science ®Google Scholar

▪ Websites

• WHO: Cancer 2009 www.who.int/mediacentre/factsheets/fs297/en/index.html
   Google Scholar
• SEER Cancer Statistics Review, 1975–2007. Altekruse SF, Krapcho M, Neyman N et al. (Eds) (2010) http://seer.cancer.gov/csr/1975_2007/
   Google Scholar
• Programs UDoEG: Human Genome Project Information http://genomics.energy.gov
   Google Scholar
• NIH: The Cancer Genome Atlas – Mission and Goals http://cancergenome.nih.gov/about/mission.asp
   Google Scholar